Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 440

1.

Biochemical and Proteomic Characterization of Recombinant Human α/β Hydrolase Domain 6.

Shields CM, Zvonok N, Zvonok A, Makriyannis A.

Sci Rep. 2019 Jan 29;9(1):890. doi: 10.1038/s41598-018-36633-4.

2.

Crystal Structure of the Human Cannabinoid Receptor CB2.

Li X, Hua T, Vemuri K, Ho JH, Wu Y, Wu L, Popov P, Benchama O, Zvonok N, Locke K, Qu L, Han GW, Iyer MR, Cinar R, Coffey NJ, Wang J, Wu M, Katritch V, Zhao S, Kunos G, Bohn LM, Makriyannis A, Stevens RC, Liu ZJ.

Cell. 2019 Jan 24;176(3):459-467.e13. doi: 10.1016/j.cell.2018.12.011. Epub 2019 Jan 10.

PMID:
30639103
3.

Efficacy and safety of a fatty acid amide hydrolase inhibitor (PF-04457845) in the treatment of cannabis withdrawal and dependence in men: a double-blind, placebo-controlled, parallel group, phase 2a single-site randomised controlled trial.

D'Souza DC, Cortes-Briones J, Creatura G, Bluez G, Thurnauer H, Deaso E, Bielen K, Surti T, Radhakrishnan R, Gupta A, Gupta S, Cahill J, Sherif MA, Makriyannis A, Morgan PT, Ranganathan M, Skosnik PD.

Lancet Psychiatry. 2019 Jan;6(1):35-45. doi: 10.1016/S2215-0366(18)30427-9. Epub 2018 Dec 6.

PMID:
30528676
4.

Cannabinoid CB2 Agonist AM1710 Differentially Suppresses Distinct Pathological Pain States and Attenuates Morphine Tolerance and Withdrawal.

Li AL, Lin X, Dhopeshwarkar AS, Thomaz AC, Carey LM, Liu Y, Nikas SP, Makriyannis A, Mackie K, Hohmann AG.

Mol Pharmacol. 2019 Feb;95(2):155-168. doi: 10.1124/mol.118.113233. Epub 2018 Nov 30.

PMID:
30504240
5.

Cannabinoid-induced lower lip retraction in rats.

Chopda GR, Nikas SP, Sharma R, Kulkarni S, Makriyannis A, Paronis CA.

Psychopharmacology (Berl). 2018 Nov 20. doi: 10.1007/s00213-018-5125-z. [Epub ahead of print]

PMID:
30460515
6.

Synthesis and evaluation of potent and selective MGL inhibitors as a glaucoma treatment.

Alapafuja SO, Malamas MS, Shukla V, Zvonok A, Miller S, Daily L, Rajarshi G, Miyabe CY, Chandrashekhar H, Wood J, Tyukhtenko S, Straiker A, Makriyannis A.

Bioorg Med Chem. 2019 Jan 1;27(1):55-64. doi: 10.1016/j.bmc.2018.11.003. Epub 2018 Nov 3.

PMID:
30446439
7.

Aliphatic Azides as Selective Cysteine Labeling Reagents for Integral Membrane Proteins.

Szymanski D, Papanastasiou M, Pandarinathan L, Zvonok N, Janero DR, Pavlopoulos S, Vouros P, Makriyannis A.

J Med Chem. 2018 Nov 16. doi: 10.1021/acs.jmedchem.8b01302. [Epub ahead of print]

PMID:
30444608
8.

Inhibition of N-acylethanolamine acid amidase reduces nicotine-induced dopamine activation and reward.

Sagheddu C, Scherma M, Congiu M, Fadda P, Carta G, Banni S, Wood JT, Makriyannis A, Malamas MS, Pistis M.

Neuropharmacology. 2019 Jan;144:327-336. doi: 10.1016/j.neuropharm.2018.11.013. Epub 2018 Nov 12.

PMID:
30439418
9.

Brain-Permeant and -Impermeant Inhibitors of Fatty Acid Amide Hydrolase Synergize with the Opioid Analgesic Morphine to Suppress Chemotherapy-Induced Neuropathic Nociception Without Enhancing Effects of Morphine on Gastrointestinal Transit.

Slivicki RA, Saberi SA, Iyer V, Vemuri VK, Makriyannis A, Hohmann AG.

J Pharmacol Exp Ther. 2018 Dec;367(3):551-563. doi: 10.1124/jpet.118.252288. Epub 2018 Oct 1.

PMID:
30275151
10.

Fluorescent probes for G-protein-coupled receptor drug discovery.

Iliopoulos-Tsoutsouvas C, Kulkarni RN, Makriyannis A, Nikas SP.

Expert Opin Drug Discov. 2018 Oct;13(10):933-947. doi: 10.1080/17460441.2018.1518975. Epub 2018 Sep 24.

PMID:
30249143
11.

Endocannabinoid Metabolome Characterization of Transitional and Mature Human Milk.

Gaitán AV, Wood JT, Zhang F, Makriyannis A, Lammi-Keefe CJ.

Nutrients. 2018 Sep 12;10(9). pii: E1294. doi: 10.3390/nu10091294.

12.

( R)- N-(1-Methyl-2-hydroxyethyl)-13-( S)-methyl-arachidonamide (AMG315): A Novel Chiral Potent Endocannabinoid Ligand with Stability to Metabolizing Enzymes.

Liu Y, Ji L, Eno M, Kudalkar S, Li AL, Schimpgen M, Benchama O, Morales P, Xu S, Hurst D, Wu S, Mohammad KA, Wood JT, Zvonok N, Papahatjis DP, Zhou H, Honrao C, Mackie K, Reggio P, Hohmann AG, Marnett LJ, Makriyannis A, Nikas SP.

J Med Chem. 2018 Oct 11;61(19):8639-8657. doi: 10.1021/acs.jmedchem.8b00611. Epub 2018 Sep 21.

PMID:
30196704
13.

Reversal of albuminuria by combined AM6545 and perindopril therapy in experimental diabetic nephropathy.

Barutta F, Bellini S, Mastrocola R, Gambino R, Piscitelli F, di Marzo V, Corbetta B, Vemuri VK, Makriyannis A, Annaratone L, Bruno G, Gruden G.

Br J Pharmacol. 2018 Dec;175(23):4371-4385. doi: 10.1111/bph.14495. Epub 2018 Nov 6.

PMID:
30184259
14.

Oximes short-acting CB1 receptor agonists.

Malamas MS, Raghav JG, Ma X, Honrao C, Wood JT, Benchama O, Zhou H, Mallipeddi S, Makriyannis A.

Bioorg Med Chem. 2018 Oct 1;26(18):4963-4970. doi: 10.1016/j.bmc.2018.08.003. Epub 2018 Aug 2.

PMID:
30122284
15.

The novel peripherally active cannabinoid type 1 and serotonin type 3 receptor agonist AM9405 inhibits gastrointestinal motility and reduces abdominal pain in mouse models mimicking irritable bowel syndrome.

Salaga M, Binienda A, Tichkule RB, Thakur GA, Makriyannis A, Storr M, Fichna J.

Eur J Pharmacol. 2018 Oct 5;836:34-43. doi: 10.1016/j.ejphar.2018.08.016. Epub 2018 Aug 17.

PMID:
30121173
16.

Endocannabinoid regulation of homeostatic feeding and stress-induced alterations in food intake in male rats.

Sticht MA, Lau DJ, Keenan CM, Cavin JB, Morena M, Vemuri VK, Makriyannis A, Cravatt BF, Sharkey KA, Hill MN.

Br J Pharmacol. 2018 Jul 26. doi: 10.1111/bph.14453. [Epub ahead of print]

PMID:
30051485
17.

Cannabinoid CB1 receptor neutral antagonist AM4113 inhibits heroin self-administration without depressive side effects in rats.

He XH, Jordan CJ, Vemuri K, Bi GH, Zhan J, Gardner EL, Makriyannis A, Wang YL, Xi ZX.

Acta Pharmacol Sin. 2019 Mar;40(3):365-373. doi: 10.1038/s41401-018-0059-x. Epub 2018 Jul 2.

PMID:
29967454
18.

Controlled-Deactivation CB1 Receptor Ligands as a Novel Strategy to Lower Intraocular Pressure.

Miller S, Kulkarni S, Ciesielski A, Nikas SP, Mackie K, Makriyannis A, Straiker A.

Pharmaceuticals (Basel). 2018 May 22;11(2). pii: E50. doi: 10.3390/ph11020050.

19.

Hydrogen-Deuterium Exchange Mass Spectrometry to Study Protein Complexes.

Kochert BA, Iacob RE, Wales TE, Makriyannis A, Engen JR.

Methods Mol Biol. 2018;1764:153-171. doi: 10.1007/978-1-4939-7759-8_10.

PMID:
29605914
20.

A lethal synergy induced by phellinus linteus and camptothecin11 in colon cancer cells.

Yu T, Ganapathy S, Shen L, Peng B, Kim SH, Makriyannis A, Chen C.

Oncotarget. 2018 Jan 4;9(5):6308-6319. doi: 10.18632/oncotarget.23918. eCollection 2018 Jan 19.

21.

Expression, Purification and Characterization of the Human Cannabinoid 1 Receptor.

Mallipeddi S, Zvonok N, Makriyannis A.

Sci Rep. 2018 Feb 13;8(1):2935. doi: 10.1038/s41598-018-19749-5.

22.

Effects of Distal Mutations on the Structure, Dynamics and Catalysis of Human Monoacylglycerol Lipase.

Tyukhtenko S, Rajarshi G, Karageorgos I, Zvonok N, Gallagher ES, Huang H, Vemuri K, Hudgens JW, Ma X, Nasr ML, Pavlopoulos S, Makriyannis A.

Sci Rep. 2018 Jan 29;8(1):1719. doi: 10.1038/s41598-017-19135-7.

23.

Long-Lasting In Vivo Effects of the Cannabinoid CB1 Antagonist AM6538.

Paronis CA, Chopda GR, Vemuri K, Zakarian AS, Makriyannis A, Bergman J.

J Pharmacol Exp Ther. 2018 Mar;364(3):485-493. doi: 10.1124/jpet.117.245647. Epub 2018 Jan 8.

24.

Secretion, isotopic labeling and deglycosylation of N-acylethanolamine acid amidase for biophysical studies.

Pavlopoulos S, Pelekoudas DN, Benchama O, Rawlins CM, Agar JN, West JM, Malamas M, Zvonok N, Makriyannis A.

Protein Expr Purif. 2018 May;145:108-117. doi: 10.1016/j.pep.2017.12.005. Epub 2017 Dec 15.

PMID:
29253688
25.

Cannabinoid-1 receptor neutral antagonist reduces binge-like alcohol consumption and alcohol-induced accumbal dopaminergic signaling.

Balla A, Dong B, Shilpa BM, Vemuri K, Makriyannis A, Pandey SC, Sershen H, Suckow RF, Vinod KY.

Neuropharmacology. 2018 Mar 15;131:200-208. doi: 10.1016/j.neuropharm.2017.10.040. Epub 2017 Nov 3.

26.

Adipocyte cannabinoid receptor CB1 regulates energy homeostasis and alternatively activated macrophages.

Ruiz de Azua I, Mancini G, Srivastava RK, Rey AA, Cardinal P, Tedesco L, Zingaretti CM, Sassmann A, Quarta C, Schwitter C, Conrad A, Wettschureck N, Vemuri VK, Makriyannis A, Hartwig J, Mendez-Lago M, Bindila L, Monory K, Giordano A, Cinti S, Marsicano G, Offermanns S, Nisoli E, Pagotto U, Cota D, Lutz B.

J Clin Invest. 2017 Nov 1;127(11):4148-4162. doi: 10.1172/JCI83626. Epub 2017 Oct 16.

27.

Cannabinoid CB1 Discrimination: Effects of Endocannabinoids and Catabolic Enzyme Inhibitors.

Leonard MZ, Alapafuja SO, Ji L, Shukla VG, Liu Y, Nikas SP, Makriyannis A, Bergman J, Kangas BD.

J Pharmacol Exp Ther. 2017 Dec;363(3):314-323. doi: 10.1124/jpet.117.244392. Epub 2017 Sep 25.

28.

The role of human monoacylglycerol lipase (hMAGL) binding pocket in breakup of unsaturated phospholipid membranes.

Karageorgos I, Silin VI, Zvonok N, Marino J, Janero DR, Makriyannis A.

Anal Biochem. 2017 Nov 1;536:90-95. doi: 10.1016/j.ab.2017.08.009. Epub 2017 Aug 17.

PMID:
28822686
29.

Inhibitor of Endocannabinoid Deactivation Protects Against In Vitro and In Vivo Neurotoxic Effects of Paraoxon.

Farizatto KLG, McEwan SA, Naidoo V, Nikas SP, Shukla VG, Almeida MF, Byrd A, Romine H, Karanian DA, Makriyannis A, Bahr BA.

J Mol Neurosci. 2017 Sep;63(1):115-122. doi: 10.1007/s12031-017-0963-4. Epub 2017 Aug 12.

PMID:
28803438
30.

Ligand-Assisted Protein Structure (LAPS): An Experimental Paradigm for Characterizing Cannabinoid-Receptor Ligand-Binding Domains.

Janero DR, Korde A, Makriyannis A.

Methods Enzymol. 2017;593:217-235. doi: 10.1016/bs.mie.2017.06.022. Epub 2017 Jul 3.

PMID:
28750804
31.

CB₁ receptor antagonism in the bed nucleus of the stria terminalis interferes with affective opioid withdrawal in rats.

Wills KL, DeVuono MV, Limebeer CL, Vemuri K, Makriyannis A, Parker LA.

Behav Neurosci. 2017 Aug;131(4):304-11. doi: 10.1037/bne0000201.

PMID:
28714716
32.

Crystal structures of agonist-bound human cannabinoid receptor CB1.

Hua T, Vemuri K, Nikas SP, Laprairie RB, Wu Y, Qu L, Pu M, Korde A, Jiang S, Ho JH, Han GW, Ding K, Li X, Liu H, Hanson MA, Zhao S, Bohn LM, Makriyannis A, Stevens RC, Liu ZJ.

Nature. 2017 Jul 27;547(7664):468-471. doi: 10.1038/nature23272. Epub 2017 Jul 5.

33.

C1'-Azacycloalkyl Hexahydrocannabinols.

Ho TC, Shimada N, Tius MA, Nikas SP, Zhang W, Makriyannis A.

J Org Chem. 2017 Aug 4;82(15):7839-7849. doi: 10.1021/acs.joc.7b00988. Epub 2017 Jul 17.

PMID:
28677397
34.

s signalling of the CB1 receptor and the influence of receptor number.

Finlay DB, Cawston EE, Grimsey NL, Hunter MR, Korde A, Vemuri VK, Makriyannis A, Glass M.

Br J Pharmacol. 2017 Aug;174(15):2545-2562. doi: 10.1111/bph.13866. Epub 2017 Jun 19.

35.

Suppression of PKC causes oncogenic stress for triggering apoptosis in cancer cells.

Ganapathy S, Peng B, Shen L, Yu T, Lafontant J, Li P, Xiong R, Makriyannis A, Chen C.

Oncotarget. 2017 May 9;8(19):30992-31002. doi: 10.18632/oncotarget.16047.

36.

Dual therapy targeting the endocannabinoid system prevents experimental diabetic nephropathy.

Barutta F, Grimaldi S, Gambino R, Vemuri K, Makriyannis A, Annaratone L, di Marzo V, Bruno G, Gruden G.

Nephrol Dial Transplant. 2017 Oct 1;32(10):1655-1665. doi: 10.1093/ndt/gfx010.

PMID:
28387811
37.

Binding Site Characterization of AM1336, a Novel Covalent Inverse Agonist at Human Cannabinoid 2 Receptor, Using Mass Spectrometric Analysis.

Mallipeddi S, Kreimer S, Zvonok N, Vemuri K, Karger BL, Ivanov AR, Makriyannis A.

J Proteome Res. 2017 Jul 7;16(7):2419-2428. doi: 10.1021/acs.jproteome.7b00023. Epub 2017 Jun 19.

PMID:
28374590
38.

Human Cannabinoid Receptor 2 Ligand-Interaction Motif: Transmembrane Helix 2 Cysteine, C2.59(89), as Determinant of Classical Cannabinoid Agonist Activity and Binding Pose.

Zhou H, Peng Y, Halikhedkar A, Fan P, Janero DR, Thakur GA, Mercier RW, Sun X, Ma X, Makriyannis A.

ACS Chem Neurosci. 2017 Jun 21;8(6):1338-1347. doi: 10.1021/acschemneuro.7b00003. Epub 2017 Mar 1.

PMID:
28220706
39.

Differential effects of cannabinoid CB1 inverse agonists and antagonists on impulsivity in male Sprague Dawley rats: identification of a possibly clinically relevant vulnerability involving the serotonin 5HT1A receptor.

McLaughlin PJ, Jagielo-Miller JE, Plyler ES, Schutte KK, Vemuri VK, Makriyannis A.

Psychopharmacology (Berl). 2017 Mar;234(6):1029-1043. doi: 10.1007/s00213-017-4548-2. Epub 2017 Feb 1.

PMID:
28144708
40.

N-acylethanolamine-hydrolyzing acid amidase and fatty acid amide hydrolase inhibition differentially affect N-acylethanolamine levels and macrophage activation.

Alhouayek M, Bottemanne P, Makriyannis A, Muccioli GG.

Biochim Biophys Acta Mol Cell Biol Lipids. 2017 May;1862(5):474-484. doi: 10.1016/j.bbalip.2017.01.001. Epub 2017 Jan 6.

PMID:
28065729
41.

Two Janus Cannabinoids That Are Both CB2 Agonists and CB1 Antagonists.

Dhopeshwarkar A, Murataeva N, Makriyannis A, Straiker A, Mackie K.

J Pharmacol Exp Ther. 2017 Feb;360(2):300-311. doi: 10.1124/jpet.116.236539. Epub 2016 Dec 7.

42.

Functional selectivity at G-protein coupled receptors: Advancing cannabinoid receptors as drug targets.

Mallipeddi S, Janero DR, Zvonok N, Makriyannis A.

Biochem Pharmacol. 2017 Mar 15;128:1-11. doi: 10.1016/j.bcp.2016.11.014. Epub 2016 Nov 24. Review.

43.

Prophylactic treatment with the tricyclic antidepressant desipramine prevents development of paclitaxel-induced neuropathic pain through activation of endogenous analgesic systems.

Deng L, Lee WH, Xu Z, Makriyannis A, Hohmann AG.

Pharmacol Res. 2016 Dec;114:75-89. doi: 10.1016/j.phrs.2016.10.007. Epub 2016 Oct 20.

44.

Crystal Structure of the Human Cannabinoid Receptor CB1.

Hua T, Vemuri K, Pu M, Qu L, Han GW, Wu Y, Zhao S, Shui W, Li S, Korde A, Laprairie RB, Stahl EL, Ho JH, Zvonok N, Zhou H, Kufareva I, Wu B, Zhao Q, Hanson MA, Bohn LM, Makriyannis A, Stevens RC, Liu ZJ.

Cell. 2016 Oct 20;167(3):750-762.e14. doi: 10.1016/j.cell.2016.10.004.

45.

Ral A, via activating the mitotic checkpoint, sensitizes cells lacking a functional Nf1 to apoptosis in the absence of protein kinase C.

Ganapathy S, Fagman JB, Shen L, Yu T, Zhou X, Dai W, Makriyannis A, Chen C.

Oncotarget. 2016 Dec 20;7(51):84326-84337. doi: 10.18632/oncotarget.12607.

46.

Acute and chronic effects of cannabidiol on Δ⁹-tetrahydrocannabinol (Δ⁹-THC)-induced disruption in stop signal task performance.

Jacobs DS, Kohut SJ, Jiang S, Nikas SP, Makriyannis A, Bergman J.

Exp Clin Psychopharmacol. 2016 Oct;24(5):320-330. Epub 2016 Aug 15.

47.

The CB1 Neutral Antagonist AM4113 Retains the Therapeutic Efficacy of the Inverse Agonist Rimonabant for Nicotine Dependence and Weight Loss with Better Psychiatric Tolerability.

Gueye AB, Pryslawsky Y, Trigo JM, Poulia N, Delis F, Antoniou K, Loureiro M, Laviolette SR, Vemuri K, Makriyannis A, Le Foll B.

Int J Neuropsychopharmacol. 2016 Dec 30;19(12). pii: pyw068. doi: 10.1093/ijnp/pyw068. Print 2016 Dec.

48.

Novel C-Ring-Hydroxy-Substituted Controlled Deactivation Cannabinergic Analogues.

Kulkarni S, Nikas SP, Sharma R, Jiang S, Paronis CA, Leonard MZ, Zhang B, Honrao C, Mallipeddi S, Raghav JG, Benchama O, Järbe TU, Bergman J, Makriyannis A.

J Med Chem. 2016 Jul 28;59(14):6903-19. doi: 10.1021/acs.jmedchem.6b00717. Epub 2016 Jul 13.

49.

A high efficacy cannabinergic ligand (AM4054) used as a discriminative stimulus: Generalization to other adamantyl analogs and Δ(9)-THC in rats.

Järbe TU, LeMay BJ, Thakur GA, Makriyannis A.

Pharmacol Biochem Behav. 2016 Sep;148:46-52. doi: 10.1016/j.pbb.2016.06.001. Epub 2016 Jun 2.

50.

Tolerance to the Diuretic Effects of Cannabinoids and Cross-Tolerance to a κ-Opioid Agonist in THC-Treated Mice.

Chopda GR, Parge V, Thakur GA, Gatley SJ, Makriyannis A, Paronis CA.

J Pharmacol Exp Ther. 2016 Aug;358(2):334-41. doi: 10.1124/jpet.116.232132. Epub 2016 May 26.

Supplemental Content

Loading ...
Support Center